Simple blood and tissue tests could revolutionize lung cancer care

NCT ID NCT05665504

Recruiting now Diagnosis Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether certain biomarkers in blood and lung tissue can help doctors tell if a lung nodule is cancer, predict the risk of cancer coming back after surgery, and monitor for late recurrence. Researchers will follow 250 people with suspicious lung nodules or recent lung cancer surgery. The goal is to improve diagnosis and personalize follow-up care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DetermaRX (tissue biomarker test), LCDT-1, NodifyXL2, CIZ1b (blood biomarker tests)
What this could lead to: If successful, these biomarker tests could help doctors more accurately diagnose lung nodules, decide who needs chemotherapy after surgery, and catch cancer returning earlier.
What could go wrong: This is an observational study, not a treatment trial. The tests may not prove accurate enough to change standard care, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma lung cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA OF LUNG LUNG; NODE

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.